Cardiovascular Disease Diagnostics: Market Research Report

Date: April 1, 2012
Pages: 498
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C89E3B46618EN
Leaflet:

Download PDF Leaflet

Cardiovascular Disease Diagnostics: Market Research Report
This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following Two Broad Segments: In Vitro Diagnostics, and In Vivo Diagnostics.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America.

The report profiles 70 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Cholestech Corp., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biomérieux, Cambridge Heart, Inc., GE HealthCare, Home Access Health Corporation, LifeSign LLC, Liposcience, Inc., Nanosphere, Inc., Ortho-Clinical Diagnostics, Inc., Philips Healthcare, Polymer Technology Systems, Inc., Response Biomedical Corp., Roche Diagnostics, Siemens Healthcare Diagnostics, Inc., St. Jude Medical, Inc., and EP MedSystems.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
In Vitro Diagnostics
In Vivo Diagnostics

II. EXECUTIVE SUMMARY1.INDUSTRY OVERVIEW

Cardiovascular Diseases - Facts and Figures
Cardiovascular Diseases: The Undying Challenge

Table 1. Region-Wise Incidence and Prevalence of Cardiovascular Diseases in 2006

Mounting Healthcare Costs - Calls for Early Diagnosis
Cardiovascular Disease Diagnostics: Playing a Pivotal Role in Early Disease Detection
Fast and Accurate Diagnosis – Reduce Unnecessary Healthcare Costs
POC Diagnostics Market Gains Momentum
Cardiac Markers - Making Diagnosis Easier and Quicker
Major Cardiac Markers and their Properties
What’s New in POC Cardiac Markers Space?
Leading Players
List of Point of Care Cardiac Marker Testing Products

2.IN-VIVO DIAGNOSTICS

Novel Imaging Techniques Boost In vivo Diagnostics Market
Non-Invasive Procedure Hogs the Limelight for Cardiovascular Treatment
Cardiology Diagnostic Imaging
New Technologies Bring Diagnostics Closer to Patients
Trends Cited in the Imaging Technologies Market
CT Scanners
MRI
Move Towards Efficient Patient Data Management

3.IN-VITRO DIAGNOSTICS

A Quick Insight into the Global In-vitro Diagnostics Market
Growth Trends
Developed Countries Drive In-Vitro Diagnostics (IVD) Market

Table 2. Leading In-Vitro Diagnostics Markets Worldwide (2011): Percentage Breakdown for North America, Europe, Japan, and Others (includes corresponding Graph/Chart)

Established Players Dominate the Fragmented Market

Table 3. Leading Players in the Global In-Vitro Diagnostics Market (2011): Percentage Breakdown of Value Sales for Roche Diagnostics, Bayer/Siemens, Abbott Diagnostics, Ortho/LifeScan, Beckman Coulter, BD, and Others (includes corresponding Graph/Chart)

Point-of-Care In-Vitro Testing on the Roll

Table 4. Global In vitro Diagnostics Market by Type of Test (2011): Percentage Breakdown for Central Lab Testing, Point-of-Care Testing, and Molecular Testing (includes corresponding Graph/Chart)

A Specific Focus on Global Cardiovascular In-Vitro Diagnostics Market
Aging Population Drives Home Testing Market
Cholesterol and Other Cardiovascular Test Kits Offered by Leading Companies
Development of Home Cholesterol Testing Kits

Table 5. Global Cholesterol Point-of-Care Rapid Tests Market (2011): Market Shares of Leading Players by Value Sales for Inverness Medical, Roche, Abaxis, and Others (includes corresponding Graph/Chart)

Strong Demand for Risk Assessment Markers
Advancements in Alternate-Site Coagulation Monitoring

4.CVD - CAUSE AND RISK FACTORS

CVD - Global Facts

Table 6. CVD Death Rates (per 100,000 population) Among Men (Aged 35-74 years) by Select Country: 2007 (includes corresponding Graph/Chart)
Table 7. CVD Death Rates (per 100,000 population) Among Women (Aged 35-74 years) by Select Country: 2007 (includes corresponding Graph/Chart)

Atherosclerosis - Leading Cause for CVD
Risk Factors
Irreversible Risk Factors
Increasing age
Sex (gender)
Heredity (including Race)
Risk Factors that can be controlled
Tobacco Smoke
High Blood Cholesterol
LDL Cholesterol
HDL Cholesterol
Triglyceride levels
Hypercholesterolemia - Conditions Associated with Cholesterol Level
High Blood Pressure
BP - Leading Cause of Cardiovascular Disease in Young Adults
Physical Inactivity
Obesity and Overweight
Diabetes Mellitus
Cardiovascular Disease and Homocysteine Levels
Measures for Reducing Cardiovascular Diseases

5.CARDIOVASCULAR DISEASE AND CONDITIONS

Angina Pectoris
Arrhythmias
Sudden Cardiac Death (SCD)
Stroke
Congestive Heart Failure
Heart Failure Classification as per the NYHA and ACC/AHA

Table 8. Prevalence Rates of Congestive Heart Failure in Select Countries (per 10,000) (includes corresponding Graph/Chart)

Cardiovascular Disease Involving Transplant Patients

6.DIAGNOSTIC TESTS FOR CARDIOVASCULAR DISEASES

In-Vitro Cardiovascular Diagnostics
Cholesterol Testing
Use of Markers
Creatine Kinase MB
Troponin T and Troponin I
C-Reactive Protein
Plasminogen Activator Inhibitor-1
D-Dimer
Thrombus Precursor Protein
Other Cardiac Markers
Increasing Popularity of Risk Assessment Markers
A Step Forward in Cardiovascular Risk Assessment
In Vivo Diagnostic Tests
Computed Imaging / Tomography
Electron Beam Computed Tomography (EBCT)
Appropriate Conditions for EBCT Diagnosis
Cardiac Positron Emission Tomography (PET)
Digital Cardiac Angiography/ Digital Subtraction Angiography
Magnetic Resonance Imaging (MRI)
Single Photon Emission Computed Tomography (SPECT)
Echocardiography
Different Types of Echo-techniques
M-mode (Motion mode, One-dimensional)
Two-Dimensional (Cross-sectional)
Stress Echocardiogram (Stress Echo)
Transesophageal Echocardiogram (TEE)
Risks
Ultrasound Tests
Doppler Ultrasound
Intravascular Ultrasound
Working
Comparative Facts Related to Definitive Diagnosis of Cardiovascular Disease
Nuclear Cardiology Tests
Applications
Types of Nuclear Cardiology Tests
Myocardial Perfusion Imaging
Applications
Risks
Ventricular Function Test
Testing Cardiac Stress
Cardio Vascular Disease Diagnostics Tests in the Pipeline
Aderis MRE-0470
CardioMEMS Novel Technology
Technology Platform

7.PRODUCT LAUNCHES AND DEVELOPMENTS

Cardiac Science Launches Microvolt T-Wave Alternans Module
Cleveland HeartLab to Extend Test Menu
St. Jude Medical Introduces EnSite Derexi Module
NorDiag Unveils NorDiags Arrow Instrument
Biosense Webster Launches CARTO® 3 System
McKesson Unveils New Variant of Horizon Cardiology Cardiovascular Information System
Correlagen Launches CardioGeneScan Test
Royal Philips Electronics to Launch PageWriter TC50 Cardiograph
Philips Introduces Xcelera R3.1
St. Jude Medical Launches Medical Devices for Heart Rhythms Disorders

8.PRODUCT LAUNCHES AND DEVELOPMENTS – A HISTORIC PERSPECTIVE BUILDER

TomTec and Medis Launches Cardiac Imaging and Analysis Product
Royal Philips Electronics Launches PageWriter TC70
Philips Healthcare to Introduce CX50 CompactXtreme
Royal Philips Electronics Introduces Xcelera R2.2
Toshiba America to Launch AplioTM Artida
Philips Rolls Out 256-slice CT scanner, Brilliance iCT Scanner
Royal Philips Launches Live 3D Transesophageal Echocardiogram Probe
GE Healthcare Launches Vivid e Ultrasound Systems
Cardionetics Launches ECG Monitor for 24-Hour Real-Time Cardiac Diagnosis
Siemens Launches Imaging Release for the ACUSON Sequoia Platform
GE Healthcare Launches Version 2.0 of Centricity Cardiology CA1000
GE Healthcare Introduces New Capabilities to CardioSoft Diagnostic Software
GE Healthcare’s Lightspeed VCT Offers Imaging at 70% Lower Exposure
Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker System (Outside US)
Royal Philips Launches New Imaging Tool for Complex Cardiac Arrhythmias
Siemens Medical Introduces syngo® US, New Echocardiography Solution.
Dade Behring Introduces CardioPhase® hsCRP Test for Multiple Testing Platforms.
Shimadzu Launches Two Models in Angiographic Imaging
Omron Healthcare Introduces Non Invasive Vascular Profiling System
Abbott Launches XIENCE V, New Coronary Stent System
Siemens Medical Introduces Acuson AcuNav 8F, an Advanced Ultrasound Catheter…
BioMérieux Introduces High Performance VIDAS Troponin I Ultra
Siemens Launches Acuson X300 Ultrasound Platform
Siemens Releases Web-Enabled CT
GE Introduces Latest Electrocardiograph Device, MAC 3500
GE Emphasizes on the Striking Features of New Vivid 7 Dimension ’06
GE Launches Latest Innova Digital Flat Panel Biplane Imaging Devices
Medtronic Introduces Latest Range of Implantable Cardiac Defibrillators
Philips Introduces Web Based Cardiac Tools
Siemens Showcases Solutions for Cardiac Problems Through Molecular Imaging
Siemens Presents Advancements in Echocardiography
Siemens Debuts syngo BEAT
Siemens Combines syngo® Dynamics with Soarian® for Cardiovascular EPR
GE Healthcare Unveils CardIQ Fusion
GE Introduces Discovery VCT
GE Unveils Dynamic VUE
GE Launches CardIQ Xpress
GE Presents the Ventri for Cardiac Imaging
GE Introduces High Definition Magnetic Resonance System
Dade Behring Unveils CardioPhase(R) hsCRP Test
Siemens Launches Encompass III on C512 Ultrasound Platform
Siemens Launches Four New CT Clinical Engines
Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool
Corgenix Introduces Predictive Cardiovascular Diagnostic Kit, AtherOx™
Philips Introduces HD11 XE Cardiology Ultrasound System
Siemens Introduces Biplane FD Cardiology System
Siemens Introduces Syngo Circulation Software for CT Tomography
Siemens Introduces SOMATOM Definition for Cardiac Imaging
Dade Behring Unveils Homocysteine Test on BN (TM) Systems
Roche Unveils Cardiac pro-BNP Test
Philips Introduces HD11 XE
Corgenix Unveils AtherOx(TM)
GE Healthcare Unveils Breakthrough Imaging Technology
Philips Launches Products to Detect Heart Problems
Philips Unveils Computed Tomography and EP Planning package
Philips Widens Magnetic Resonance Portfolio
New Cardiac Monitoring Products from Philips
Siemens Launches Image-Arena
Siemens Announces New Procam-Calculator Combined with CT Examination
Siemens Medical Solutions Launches Axiom Artis dTA
GE Healthcare Unveils Vivid i
GE Healthcare Presents Fully Integrated 4D Cardiovascular Ultrasound System
GE Healthcare Debuts New Imaging System
New Discovery PET/CT Systems from GE Healthcare
SonoSite Presents SonoCalc IMT Software
Dade Behring Introduces High Sensitivity Troponin I Assay
Biosite Unveils New Diagnostic Test
MDS Diagnostic Services Unveils New Test to Prevent Heart Disease
diaDexus Develops PLAC Test
Siemens Introduces New Nuclear Cardiology Imaging System
Roche Diagnostics Receives U.S. Clearance and European CE Mark
Camtronics Unveils Cardiovascular Screening Software
Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment Test

9.RECENT INDUSTRY ACTIVITY

Danaher Acquires Beckman Coulter
Inverness Changes Name to Alere
Miraculins Acquires PreMD’s PREVU(i) Skin Cholesterol Test Assets
Kardia Health Systems Partners with TomTec Imaging Systems
TriLink and Biofortuna Ink Licensing Agreement
Corgenix Enters into a Strategic Alliance with ELITech
VaxGen to Merge with diaDexus
St. Jude Medical to Take Over LightLab Imaging
GE Healthcare and CardioDx Enter into Strategic Alliance
bioMerieux and Knome Ink Strategic Partnership Agreement
Merge Healthcare Acquires AMICAS
Diamedix and Nova Ink Distribution Agreement
Inverness Acquires Standard Diagnostics
Quidel Acquires Diagnostic Hybrids
bioMérieux Acquires Meikang Biotech
Aurora Health Care Partners with Celera
Mediscience Technology Corporation Acquires SensiVida Medical Systems
Volcano Acquires Axsun Technologies
Thermo Fisher Takes Over B.R.A.H.M.S.
SonoSite Acquires CardioDynamics International
IntriCon Snaps Up Datrix
ST. Jude Medical Receives US FDA and European Approval for EnSite Velocity™ Cardiac Mapping System

10.STRATEGIC CORPORATE DEVELOPMENTS – A HISTORIC PERSPECTIVE BUILDER

Roche Inks Agreement with Response Biomedical
Dynatek Dalta Scientific Inks Agreement with State Food and Drug Administration
Amic Inks Licensing Deal with Roche Diagnostics
TRICARE Includes Atherotech’s VAP® Test
PreMD Receives NSE Letter from US FDA for POC Skin Cholesterol Test
Amic Gains License for Roche’s Cardiac Marker
diaDexus and Fisher HealthCare Sign Agreement
Inverness Inks Distribution Agreement with PrognostiX
GE Healthcare Enters into Collaboration with Boston Scientific
St. Jude Medical Acquires EP MedSystems
Inverness Takes Over Biosite
Siemens Medical Acquires Dade Behring
Inverness Medical Innovations Acquires Cholestech
Acrongenomics, Pearson and Molecular Enter into Joint Venture
Cholestech Teams Up with Onsite Health Diagnostics
Lipomics to Collaborate with Agilent Technologies to Develop Diagnostic Tests.
Transgenomic and Fiuotecnica Renew Collaboration Agreement
Alteon and BioRap Technologies Enter into an Agreement
IM Medical Acquires New Technology for Detecting Cardiovascular Diseases
Medtronic Establishes New Business Entity
Siemens Medical Acquires Bayer Healthcare’s Diagnostics Unit
Inverness Medical Innovations Completes Acquisition of HemoSense
Spacelabs Acquires Ferraris’ Cardiac Unit
Global Immune Takes over Primedical International
Siemens Acquires Diagnostics Products
Cholestech and Life Line Enter into Collaboration
LipoScience Signs an Agreement with ARUP
Philips Acquires Witt Biomedical
CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray
Biosense Enters into Strategic Partnership with Siemens Medical Solutions
Dade Behring Approved the Use of FSAP Antibodies by American Diagnostica
Abbott Receives Non-exclusive Sublicense for Diagnostic Use of PIGF
Nanogen Acquires Spectral’s Cardiac Test Division
Varian Enters into Alliance with LipoScience to Jointly Develop NMR System
Cardiac Services Professionals Establish eCardio Diagnostics
Response Biomedical Wins Nonexclusive License Rights for NT-proBNP and Troponin T
Biomerieux gains Nonexclusive License for NT-proBNP
Philips and PMI Ink an Agreement for Outpatient Facility
LipoScience Enters into an Agreement with LabCorp
Abbott and Cleveland Clinic to Co-develop Myeloperoxidase Cardiac Test
Abbott Receives 510(k) Clearance from FDA for Myoglobin Test
FDA Clears Additional Claim for Biosite’s Triage (R) BNP Test
Biosite Inks an Agreement with University of Mainz
Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay
Nanogen Acquires SYN•X Pharma
GE Takes Over Amersham Plc
St. Jude Medical Acquires Irvine Biomedical and Epicor
SonoSite Snaps Up SonoMetric
CardioDynamics Acquires Vermed
Philips and EP MedSystems Announce an Alliance Involving Electrophysiology Solutions
Toshiba and ViTAL Enters into an Alliance with Johns Hopkins University School of Medicine
Response Biomedical Collaborates with Shionogi
Terumo Signs Agreement with Spencer Technologies
Spectral Diagnostics Announces Agreement with NGC Medical
Philips Signs Agreement with Fletcher Allen Health Care
Spectral Diagnostics Enters into an Agreement with Cardinal Health
Siemens Signs Agreement with MediGuide
Biosite Enters into Agreement with DMI BioSciences
Cambridge Heart Enters into Agreement with Del Mar Reynolds
Cholestech Enters into an Agreement with Itamar Medical
Siemens Enters into a Contract with HiPGraphics
Abbott Announces US Clearance for Axis-Shield’s BNP Test for Use on AxSYM
Cholestech Announces FDA 510(k) Approval for hs-CRP Test
Dade Behring Bags FDA Clearance NT-proBNP Test
Dade Behring Receives FDA Clearance for N High Sensitivity CRP Assay
EP-4 Computerized Cardiac Stimulator Bags FDA Approval
Biosite Adds two new offices
Bayer Diagnostics Enhances BNP Assay Offering Globally
EP MedSystems Garners CE Approval for ALERT Deflectable CS Catheter in Europe
Cambridge Heart Inc. and Quinton Cardiology Systems Renew Pact
EPIX and Schering AG Extends Collaboration Agreement
Siemens Ultrasound and TomTec Imaging Systems Announces Agreement
FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative Cardiovascular Devices
Beckman Coulter Enters into Agreement with Biosite
Dade Behring Garners Non-exclusive Rights for a Key Cardiac Marker
Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc to Develop CardioGen-82®
New Lab Test from diaDexus Receives FDA Clearance
Hypertension Diagnostics Receives SDA Approval in China

11.FOCUS ON SELECT GLOBAL PLAYERS

AccuTech, LLC (USA)
Abbott Diagnostics (USA)
Alere Inc. (USA)
Cholestech Corp. (USA)
Ani Biotech Oy (Finland)
Axis-Shield PoC (UK)
Beckman Coulter, Inc. (USA)
biomérieux (France)
Cambridge Heart, Inc. (USA)
GE HealthCare (UK)
Home Access Health Corporation (USA)
LifeSign LLC (USA)
Liposcience, Inc. (USA)
Nanosphere, Inc. (USA)
Ortho-Clinical Diagnostics, Inc. (USA)
Philips Healthcare (USA)
Polymer Technology Systems, Inc. (USA)
Response Biomedical Corp. (Canada)
Roche Diagnostics (Switzerland)
Siemens Healthcare Diagnostics, Inc. (USA)
St. Jude Medical, Inc. (USA)
EP MedSystems (USA)

12.GLOBAL MARKET PERSPECTIVE

Table 9. World Recent Past, Current & Future Market Analysis for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 10. World Historic Review for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East, and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 11. World 15-Year Perspective for Cardiovascular Disease Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 12. World Recent Past, Current & Future Market Analysis for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 13. World Historic Review for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008(includes corresponding Graph/Chart)
Table 14. World 15-Year Perspective for Cardiovascular In Vitro Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 15. World Recent Past, Current & Future Market Analysis for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 16. World Historic Review for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 17. World 15-Year Perspective for Cardiovascular In Vivo Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET1.THE UNITED STATES

A. Market Analysis
  US Diagnostic Market: An Insight
  Trends and Issues
  Innovations Drive the Usage of Cardiovascular Monitoring Systems
  Cholesterol POCT Market: An Overview

Table 18. US Cholesterol Point-of-Care Testing (2011): Market Shares of Leading Players by Value Sales for Inverness Medical, Polymer Technology Systems, and Roche Diagnostics (includes corresponding Graph/Chart)

  Increasing Cardiovascular Ailments Drive Sales of Home Test Devices
  CHF Biomarkers to Spearhead the US market

Table 19. US Acute Myocardial Infarction (AMI) Diagnostics Market (2006 – A Historic Perspective Builder): Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart)
Table 20. US Congestive Heart Failure (CHF) Diagnostics Market (2006 – A Historic Perspective Builder): Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart)

  Cardiovascular Disease Prevalence in the US
  Key Statistics on Cardiovascular Diseases
  Mortality Statistics

Table 21. Prevalence of Cardiovascular Disease in the US (includes corresponding Graph/Chart)
Table 22. Percentage Breakdown of Deaths from Cardiovascular Diseases in the US (includes corresponding Graph/Chart)
Table 23. Prevalence of Cardiovascular Diseases among Americans by Age (Age 20 and Older) and Sex (includes corresponding Graph/Chart)
Table 24. A Factoid of CHD and MI (In Million) in the US

  Startling facts related to Stroke in US

Table 25. A Factoid of Stroke (In Million) in the US

  Incidence of Coronary Heart Disease
  AHA Statistics for Coronary Heart Disease
  Mortality rates of CHD

Table 26. Annual Number of Americans Having Diagnosed Heart Attack by Age and Sex (includes corresponding Graph/Chart)
Table 27. Prevalence of CHD by Age and Sex (In % population) (includes corresponding Graph/Chart)

  Arrhythmias
  CAD Diagnostics
  PVD Diagnostics
  Medicare Reimbursement Set for CPT Code 83704
  Competitive Glance
  Point-of-Care (POC) Diagnostics Market in the US

Table 28. Leading Players in the US POC Cardiac Market (2004- A Historic Perspective Builder) - Percentage Breakdown by Value Sales for Biosite, Dade Behring, Spectral Diagnostics, Roche and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 29. The US Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 30. The US Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 31. The US 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2.CANADA

A. Market Analysis
  Cardiovascular Disease Facts
B. Market Analytics

Table 32. Canadian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 33. Canadian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 34. Canadian 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3.JAPAN

  Market Analytics

Table 35. Japanese Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 36. Japanese Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 37. Japanese 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4.EUROPE

A. Market Analysis
Cardiovascular Disease – Mortality Statistics

Table 38. Leading Cause of Death Among Men in Europe (2007): Percentage Breakdown for Cardiovascular Diseases, Poisoning and Injuries, Respiratory Disease, Cancer, and Others (includes corresponding Graph/Chart)
Table 39. Leading Cause of Death Among Women in Europe (2011): Percentage Breakdown for Cardiovascular Diseases, Poisoning and Injuries, Respiratory Disease, Cancer, and Others (includes corresponding Graph/Chart)

  Cardiovascular Disease – Risk Factor Profile
  The Cardiovascular Disease Cost Burden
B. Market Analytics

Table 40. European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 41. European Historic Review for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 42. European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 43. European Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 44. European 15-Year Perspective for Cardiovascular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 45. European 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4A.FRANCE

  Market Analytics

Table 46. French Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 47. French Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 48. French 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4B.GERMANY

  Market Analytics

Table 49. German Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 50. German Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 51. German 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4C.ITALY

  Market Analytics

Table 52. Italian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 53. Italian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 54. Italian 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4D.THE UNITED KINGDOM

A. Market Analysis
  UK Cardiovascular Diseases Fact Sheet
B. Market Analytics

Table 55. The UK Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 56. The UK Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 57. The UK 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4E.SPAIN

  Market Analytics

Table 58. Spanish Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 59. Spanish Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 60. Spanish 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4F.RUSSIA

A. Market Analysis
  Major Players
B. Market Analytics

Table 61. Russian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 62. Russian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 63. Russian 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4G.REST OF EUROPE

  Market Analytics

Table 64. Rest of European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 65. Rest of European Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008(includes corresponding Graph/Chart)
Table 66. Rest of European 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

5.ASIA-PACIFIC

A. Market Analysis
  Cardiovascular Market in Asia-Pacific
  China
  Healthcare Expenditure to Grow Considerably by 2015
  In vitro Diagnostics Market Poised for Strong Growth
  Domestic Manufacturers Pose a Threat for Overseas IVD Manufacturers
  Leading Players
  Cardiovascular Disease Patients Overview
  Treatment Providers and Hospitals Overview
  Hospitals

Table 67. Cardiovascular Special Treatment Hospitals in China: 1991-2011(In numbers) (includes corresponding Graph/Chart)

  Chinese Cardiovascular Disease Treatment as a Part of Overall Health Care Industry

Table 68. Cardiovascular Disease Treatment in China: 1991-2006 (includes corresponding Graph/Chart)

  India
  In-vitro Diagnostics Market: An Untapped Market
  Taiwan
  IVD Market: A Lucrative Market for Healthcare Services
B. Market Analytics

Table 69. Asia-Pacific Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 70. Asia-Pacific Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 71. Asia-Pacific 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

6.THE MIDDLE EAST

  Market Analytics

Table 72. The Middle East Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 73. The Middle East Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 74. The Middle East 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

7.LATIN AMERICA

A. Market Analysis
  Brazil: A Growing Market for IVD

Table 75. Brazilian IVD Market by Segment (2011): Percentage Share Breakdown for Immunoassay, Hormone, Microbiology, Biochemistry, Hematology, Molecular Diagnostics, Cardiac markers, Hemostasis, and Cytology (includes corresponding Graph/Chart)

B. Market Analytics

Table 76. Latin American Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 77. Latin American Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 78. Latin American 15-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 70 (including Divisions/Subsidiaries - 82)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
Skip to top


Infectious Disease Diagnostic Markets US$ 3,500.00 Aug, 2009 · 180 pages

Ask Your Question

Cardiovascular Disease Diagnostics: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: